A wide range of retinal disorders can potentially be treated using viral vector-mediated gene therapy. The most widely used vectors for ocular gene delivery are based on adeno-associated virus (AAV), because they elicit minimal immune responses and mediate long-term transgene expression in a variety of retinal cell types. Proof-of-concept experiments have demonstrated the efficacy of AAVmediated transgene delivery in a number of animal models of inherited and acquired retinal disorders. Following extensive preclinical evaluation in large animal models, gene therapy for one form of inherited retinal degeneration due to RPE65 deficiency is now being tested in three concurrent clinical trials. Here, we review different approaches for treating inherited retinal degenerations and more common acquired retinal disorders using AAV-based vectors.
Introduction

Ocular disease as a target for gene therapy
Inherited retinal degeneration (IRD) affects around 1 in 3000 people in Europe and the United States. 1 It is a diverse group of conditions that result from mutations in any one of over 100 different genes. Many of the genes have now been identified and their functions elucidated, providing a major impetus to develop gene-based treatments. In addition, there are many more common complex acquired ocular diseases ranging from agerelated macular degeneration (AMD), glaucomatous optic neuropathy and autoimmune posterior uveitis. AMD, for instance, is the leading cause of blindness in industrialized nations, with an estimated incidence in the Western world of between 1 and 3%. 2, 3 The eye has a combination of features that make it ideally suited as a target organ for gene therapy. There are many animal models of IRD, most of which are well understood in terms of their molecular pathology and can be useful in the development of therapeutic interventions. 4, 5 The highly compartmentalized anatomy of the eye facilitates accurate delivery of therapeutic vector suspensions to specific tissues under direct visualization using microsurgical techniques. The various cell types that comprise the neuroretina can be efficiently transduced using recombinant viral vectors, allowing targeted delivery of therapeutic nucleic acids to the tissue compartment of interest. The blood-retina barrier minimizes systemic dissemination of vector and, hence, the possibility of unwanted systemic side effects following intraocular delivery. In addition, immune responses following intraocular vector administration are typically attenuated compared to those following systemic administration; a unique system of immune surveillance and modulation provides a degree of protection from immune responses directed against vector antigens that might otherwise cause inflammation and limit transgene expression. If only one eye is treated, the untreated eye may serve as a useful control. Finally the transparent anatomy of the eye enables noninvasive imaging of ocular tissues in vivo, and visual function is readily quantifiable using both psychophysical and electrophysiological parameters common in standard clinical practice.
Highly efficient, cell-type-specific transgene delivery can be achieved using recombinant AAV (rAAV)
Achieving efficient, long-term expression of transgene following intraocular delivery offers the means to target many life-long retinal disorders following a single administration of vector. Most forms of IRD are caused by mutations in genes expressed in rod and cone photoreceptors and in the retinal pigment epithelium (RPE). RPE is readily transduced by a variety of viruses, probably due to its intrinsic phagocytic capabilities and largely independent of specific receptors. Vectors based on herpes simplex virus, 6 adenovirus, 7 human immunodeficiency virus 8 and feline immunodeficiency virus 9 efficiently transduce RPE cells, and those based on equine infectious anaemia virus consistently mediate transgene expression in RPE cells and occasionally in photoreceptors. 10 However, rAAV is the only viral vector to efficiently transduce both RPE and photoreceptors. 11, 12 This is probably due to a combination of factors. Photoreceptors express the specific receptors required for the binding of some types of AAV (see below). Also the inter-photoreceptor matrix and the outer limiting membrane, protein components of the neurosensory retina, represent physical barriers that prevent larger virus particles, such as HIV (around 120 nm in size) 13 gaining access to photoreceptor cells, whereas the smaller size of mature AAV virions (around 20 nm) 14 may allow outer retinal neurons to be transduced. Intravitreal delivery of AAV2 leads to efficient ganglion cell transduction, 15, 16 offering the potential to deliver therapeutic genes to cells of the inner retina-indeed AAV2 is the only type of AAV investigated so far that is able to transduce retinal ganglion cells (RGCs) efficiently, making it the only appropriate vector for therapies targeting glaucomatous optic neuropathy. 17 These features mean that rAAV is regarded as the vector of choice for therapies aimed at inherited retinal disorders and for acquired disorders, such as AMD.
The first rAAV vectors to be described were based on AAV2, the most common serotype in humans; up to 80% of the population have circulating antibodies to AAV2, 18 while around 35% have neutralizing antibodies to AAV2. 19 The tropism of AAV2 vectors depends primarily on the route of administration-different cell types are transduced following delivery into the subretinal space, into the vitreous and into the anterior chamber. Utilizing the different serotypes of AAV, which vary in their structural protein sequences encoded by the cap gene, allows vector tropism to be further modulated according to requirement. This is primarily achieved by 'pseudotyping' the AAV vector, whereby an expression cassette based on the genome of AAV2 is packaged into a recombinant viral particle with a capsid originating from another serotype of AAV. Pseudotyped AAV vectors mediate differing patterns and kinetics of transgene expression, which considerably expands the available repertoire of AAV vectors. 20 Following subretinal delivery, AAV2/2 vectors (genome based on AAV-2 packaged in AAV-2 capsid) mediate expression in both rod and cone photoreceptors and in RPE, reaching maximal levels 6 weeks after subretinal delivery to the mouse eye. 12 Photoreceptor transduction is probably aided by the presence of membrane-associated heparan sulphate proteoglycans, a known class of AAV receptor, 21 and the coreceptors AlphaVbeta5 integrin 22 and fibroblast growth factor receptor. 23 In contrast to AAV2, AAV2/1, AAV2/5 and AAV5/5 vectors mediate gene expression of rapid onset, with evidence of expression in photoreceptors and RPE cells as early as 3-4 days after subretinal vector delivery to murine eyes. 20, 24, 25 Subretinal delivery of AAV2/5 to nonhuman primate eyes leads to efficient reporter gene expression, specifically in rod photoreceptors. 26 It has been suggested that the lack of cone cell and RPE transduction in monkey retina is due to the lack of platelet-derived growth factor receptor-A expression in these cell types, which has been shown to be a receptor required for AAV5 transduction. 27 Newly isolated serotypes deriving from humans (AAVhu29R, AAV7, AAV8 and AAV9) and from rhesus macaques (AAVrh.43 and AAV64R1) have been used to package AAV2-based genomes and the novel pseudotypes compared to AAV2/5 for their ability to transduce photoreceptors. This study showed that while all the new pseudotypes efficiently transduce photoreceptors and RPE, as does AAV2/5, AAV2/8 and 2/9 transduce the highest proportion of cone cells (up to 75% compared to AAV2/5, which transduces 35%). In addition, Mü ller cells are efficiently transduced by AAV2/9 based on reporter gene expression. 28 AAV2/8 has also been shown to have a significantly faster onset of transgene expression than AAV2/2, within 3-5 days post-injection. 31 and neutralizing antibodies against the AAV capsid are only detected in serum following treatment with a high dose and are not sufficient to attenuate transgene expression (RA, unpublished data). There is also no evidence of an antibody-mediated response against transgene products following long-term AAV-mediated expression, and animals previously injected with AAV in one eye show evidence of reporter gene expression in the fellow eye following repeat vector administration (RA, unpublished data). This excellent track record of safety allows long-term expression in dogs and nonhuman primates for up to 3 years, 32 and makes rAAV the vector of choice for stable, safe and efficient gene transfer to the eye in clinical applications.
Long-term constitutive transgene expression is not always desirable, and pharmacologically inducible expression systems offer an attractive strategy to temporally regulate the level of intraocular transgene expression in response to the systemic delivery of an appropriate drug. Dose-dependent expression of a reporter gene can be induced in the retina in vivo by single-vector and dual-vector rapamycin-inducible and tetracycline-inducible AAV vector systems. 33 A dimerizer-inducible expression system reproducibly drives dose-responsive inducible reporter gene expression in the retina of nonhuman primates with over a period of 2.5 years. 34 Furthermore, tetracycline-inducible expression of interleukin (IL)-10 by a single-vector rAAV system mediates a therapeutic effect in an experimental model of uveitis. 35 Further improvements in AAV vector design include the cloning of self-complementary genomes. This restricts the size of the expression cassette to around 2.4 Kb but results in at least two-fold higher maximal levels of expression following subretinal delivery to the mouse eye. 29, 36 Further specificity of transgene delivery can be achieved by the use of specific promoter sequences to restrict expression to the cell type of interest. The use of such promoter sequences has been extensively tested and several have been used in animal models of retinal degeneration to mediate gene replacement therapy and AAV-mediated gene therapy for retinal disorders PK Buch et al are discussed below. Many inherited retinal dystrophies would require transgene delivery to both rods and cones, and AAV-mediated reporter gene expression using a 292 bp fragment of the human rhodopsin kinase promoter efficiently achieves this aim. 37 Reporter gene expression restricted to cone photoreceptors has also been widely investigated, with the 2.1 Kb human red opsin promoter targeting expression to rodent L/M cones 38 and a 569 bp fragment of the human blue cone promoter sequence directing transgene expression in rodent S-cones. 39 AAV vectors mediate efficient gene replacement therapy in animal models of IRD due to loss-of-function mutations Proof-of-concept experiments describing the restoration of ultrastructure and function using AAV2 in the Prph2
Rd2/Rd2 mouse showed that gene replacement was a feasible therapeutic strategy in this model of retinitis pigmentosa. 40 Here, the use of a Rhodopsin promoter (2.2 Kb in length) mediated peripherin-2 expression, encoding a membrane glycoprotein essential for the formation and stability of photoreceptor outer segments, in rod cells. This allowed the formation of outer segment discs, leading to an improvement in retinal function (as assayed by electroretinography, ERG) for up to 14 weeks. 41 Longer-term improvements in function are not sustained in this model, probably due to the regulation of peripherin-2 expression levels and the failure of the intervention to delay apoptotic photoreceptor loss. rAAV-mediated gene replacement of retinitis pigmentosa GTPase regulator interacting protein (RPGRIP), a protein anchored in the photoreceptor connecting cilium, restores normal localization of retinitis pigmentosa GTPase regulator, preserving photoreceptor cells and retinal function for at least 5 months in a model of Leber's congenital amaurosis (LCA). 42 This was achieved using a small (234 bp) fragment of the murine Rhodopsin promoter. In models of X-linked recessive juvenile retinoschisis, AAV2/2-mediated expression of retinoschisin by photoreceptors and ganglion cells in adult mice results in an improvement in ERG responses but no recovery of retinal structure.
43 AAV5-mediated gene replacement at an earlier stage in the degeneration, however, by expression of retinoschisin in photoreceptor cells in young animals, results in both functional and structural improvements that are maintained for longer than 1 year. 44 Rescue of retinal degeneration in the Royal College of Surgeons rat by gene replacement of Mertk, an RPE receptor tyrosine kinase responsible for phagocytosis of shed photoreceptor outer segments, has been reported using an AAV2 vector, 45 resulting in restoration of phagocytic function and slowing of photoreceptor degeneration. Gene replacement of OA1 in a murine model of ocular albinism, which lacks a protein responsible for organization of RPE melansomes, is reported to increase melanosome numbers and, unexpectedly, to improve electroretinographic abnormalities. This suggests that gene therapy may offer some improvement in visual function in this disorder that is characterized by prominent developmental abnormalities. 46 LCA, an early-onset form of autosomal recessive retinitis pigmentosa, can be caused by defects in the gene encoding RPE65, which is an isomerase critical for normal retinoid cycling in the RPE. Individuals with defects in RPE65 have absent or very poor night vision and poor central vision with a predictably progressive degeneration. This form of LCA is a particularly attractive candidate for a clinical trial of gene replacement as affected individuals can have a relatively wellpreserved photoreceptor cell layer, despite having negligible vision. Successful AAV-mediated gene replacement therapy has been described in both rodents and large animal models for this form of LCA due to RPE65 deficiency. Following in utero intraocular vector delivery in RPE65 À/À knockout mice, rAAV-mediated expression of RPE65 results in efficient RPE transduction and rescue of photoreceptor degeneration. 47 Several groups have demonstrated proof-of-concept for gene replacement therapy in the Swedish Briard dog, a model that is homozygous for a null mutation in RPE65. These dogs have a phenotype similar to that in humans, with poor vision from early life and severely attenuated dark-and light-adapted ERG responses. rAAV-mediated RPE-specific expression of RPE65 following subretinal vector delivery results in significantly improved visual function as demonstrated by both electrophysiology and behavioural assessments, 48, 49 and stable improvement in visual function has been maintained in many animals for longer than 3 years. 50 These preclinical studies will help refine optimal vector configuration for subsequent clinical use. The first studies of AAV-mediated RPE65 gene delivery made use of a ubiquitous promoter sequence, 51 with the expression cassette packaged into AAV2 such that photoreceptors and RPE were transduced. To increase the biosafety of the vector without compromising the efficient restoration of structure and function seen in the early studies, transgene expression can be targeted exclusively to the RPE using the human RPE65 promoter packaged into the RPE-specific serotype AAV2/4. 52 These experiments demonstrate that, in some models of disease caused by loss-of-function mutations, gene replacement therapy is able to delay apoptotic cell loss, whereas other diseases may require additional neuroprotection therapies to achieve this. The demonstration of long-term functional improvement following gene replacement of RPE65 in preclinical models has supported proposals for clinical trials of rAAV-mediated gene therapy for patients with LCA, as discussed below.
Ablation of mutant genes that cause dominantly IRD can be achieved using vector-mediated RNA-based technology
In dominant retinal disorders, such as retinitis pigmentosa caused by mutations in Rhodopsin, gene replacement is not sufficient to overcome the expression of the mutant allele. In this case, therapies that ablate mutant transcripts, and then replace them with wild-type genes, are required. Knockdown of mRNA can be achieved using ribozymes, 53, 54 although using RNAi appears to be a more efficient approach. Designing unique interfering RNA molecules specific to each mutant allele is not feasible-there are over 100 dominant mutant alleles of
55 The ideal RNAi-based strategy may be to target a 5 0 untranslated region of the gene of interest, leading to the cleavage of all the transcripts for the target gene (including wild-type as well as mutant transcripts), in combination with the delivery of a wild-type gene. Alternatively, it is possible to target part of the coding sequence independent of the mutation, in combination with delivery of a wild-type sequence engineered to be resistant to degradation using the degeneracy of the genetic code. Extensive studies have demonstrated the feasibility of vector-mediated RNA interference in the central nervous system, using AAV-mediated expression of a small hairpin RNA (shRNA) that is processed intracellularly to an active form. AAV.shRNA delivery mediates improvements in motor neuron function and in neuronal morphology for at least 21 weeks in murine models of degeneration in the central nervous system. 56, 57 Following studies showing that AAV.shRNA delivery reduces Rhodopsin expression in vitro, 58 ,59 a recent report shows that in vivo expression of a human Rhodopsin transgene can be reduced by up to 90% and that a nonsilenced Rhodopsin gene can be expressed to achieve a degree of rescue. Eyes treated with the suppression-replacement construct showed some preservation of photoreceptors, indicating this approach may be useful in treating dominantly inherited retinal degenerations. 60 Despite these advances, suppressionreplacement needs to be refined to achieve greater therapeutic efficacy in a clinically relevant model of dominant retinal degeneration, and further concerns that will need to be addressed include the possibilities of off-target nonspecific responses and of a significant interferon response in vivo.
Prospects for AAV-mediated gene therapy for inherited cone dystrophies
So far, most gene therapy strategies developed in rodent models have focussed on conditions primarily affecting rod photoreceptors. This is likely due to the rod-rich nature of the rodent retina, which makes designing and assessing accurate models of cone-dominated disease challenging and the development of therapies in such models even more so. However, recent advances in rodent ERG, a better understanding of the molecular processes involved in cone dystrophies and the use of large animal models has facilitated the study of gene therapy for these conditions. The cone dystrophy most amenable to gene therapy is likely to be achromatopsia. Caused by mutations in three genes (GNAT2, 61 CNGa3
and CNGb3
63
), this group of cone-specific disorders results in complete loss of colour vision and loss of central visual acuity. Recent reports describe novel animal models that will provide vital tools in the development of gene therapy strategies for achromatopsia, 64 and AAV-mediated gene replacement has recently been shown to restore cone-mediated ERG responses to the Gnat2 cpfl3 mouse, which is homozygous for a nonsense mutation in Gnat2. 65 Using an optokinetic behavioural assay, the authors also detected improvements in visual acuity. This study provides evidence that cone-specific disorders can be effectively targeted using AAV vectors.
Vector-mediated neuroprotection and modulation of ocular angiogenesis and inflammation may be applicable to a wide range of retinal disorders
Not all gene replacement strategies prevent or delay the apoptotic loss of photoreceptors that represents the common pathological endpoint to a diverse array of retinal dystrophies, including inherited dystrophies in which degeneration is advanced at birth and acquired and multi-factorial conditions, such as AMD. Furthermore, the development of individualized corrective gene therapy strategies for patients with disorders due to very rare mutations may be unfeasible. Here, generic strategies that aim not to correct the gene defect but to ameliorate its consequences offer the possibility of widening the range of ocular conditions amenable to gene therapy. Such approaches include the localized, targeted delivery of neurotrophic factors and antiapoptotic proteins with the aim of enhancing photoreceptor survival. AAV-mediated delivery of the X-linked inhibitor of apoptosis has been shown to inhibit caspase activity and delay photoreceptor loss in models of retinitis pigmentosa caused by mutant Rhodopsin alleles. 66 Ciliary neurotrophic factor (CNTF) has been regarded as a strong candidate for use as a therapeutic neurotrophic agent, particularly as delivery of recombinant protein results in a transient enhancement of photoreceptor survival in rodent models of retinal degeneration. 67 ,68 AAV-mediated expression of genes encoding neurotrophic factors has been widely studied to achieve significant long-term protection from apoptotic cell death without the need for repeated administration. Despite delaying photoreceptor death for up to 4 months in rodent models of retinitis pigmentosa caused by mutant alleles of Rhodopsin and Peripherin-2, 69,70 AAV-mediated CNTF expression also results in significant dose-dependant deleterious effects on retinal function as assayed by ERG and behavioural tests. [71] [72] [73] When administered in combination with AAV-mediated gene replacement therapy in the Prph2
Rd2/Rd2 mouse, AAV.CNTF delivery abrogates any improvement in function expected from the gene replacement vector. The reduction in ERG amplitudes following sustained CNTF delivery is reflected in molecular changes in rod and cone photoreceptors, including the downregulation of photopigment expression caused by long-term activation of signalling molecules downstream of CNTF. 74 These molecular changes and reduction of ERG amplitudes is most marked in long-term models of disease, where retinal function is lost over the lifetime of the animal, analogous to the gradual loss of visual function seen in the clinic.
Alternative neurotrophic factors have also been investigated for their potential to delay photoreceptor apoptosis when delivered by AAV vectors, following extensive studies demonstrating their potency, when delivered as protein. 67, 75, 76 These factors include brain-derived neurotrophic factor (BDNF), pigment epithelium-derived neurotrophic factor (PEDF) and glial cell-line-derived neurotrophic factor (GDNF). AAV-mediated bFGF expression has been shown to delay photoreceptor loss for up to 4 months post-injection in a AAV-mediated gene therapy for retinal disorders PK Buch et al transgenic rat expressing a mutant Rhodopsin allele, although this was not reflected in improved retinal function as assayed by ERG. 77 Neuroprotection is potentially most valuable when used as an adjunct to gene replacement therapy, which effectively restores function but is unable to prevent or delay photoreceptor cell death. It has been shown that AAV-mediated expression of the gene encoding GDNF can enhance photoreceptor survival in two rodent models of retinitis pigmentosa, the Prph2
Rd2/Rd2 mouse and the RCS rat, and in combination with gene replacement, this translates into an additive improvement of retinal functionanimals treated with the combination of gene replacement and GDNF had up to 50% higher ERG amplitudes than those given gene replacement alone. Crucially, there appears to be no deleterious effects on retinal function as assayed by ERG. 71 AAV-mediated delivery of GDNF and other neurotrophic and antiapoptotic factors warrants further evaluation in models of disease that better reflect the pathology of human retinal degeneration, such that the evidence of efficacy in rodent models can be translated safely to the clinic.
Vector-mediated expression of therapeutic molecules also offers the possibility to interfere with pathological processes that modulate the severity of common acquired ocular disorders, including neovascularization, intraocular inflammation and glaucomatous optic neuropathy. In glaucoma, a combination of increased intraocular pressure, oxidative damage to optic nerve axons and relative ischaemia causes injury to the optic nerve head, leading to death of RGCs. 78 Many experimental models have been established to mimic features of glaucomatous optic neuropathy, and administration of neurotrophic factors can delay RGC loss following optic nerve injury. 79, 80 Following experimental axotomy of the optic nerve, delivery of an adenoviral vector encoding BDNF leads to protection from RGC death for up to 16 days, although transgene expression was short-lived due to host immune response to the vector. 81 There was a marked reduction in the expression of TrkB (the cognate BDNF receptor) following BDNF delivery, which can be partially overcome using AAV-mediated TrkB expression combined with BDNF protein delivery, allowing the transduced RGCs to respond effectively to the administration of the neurotrophic factor. 82 AAV-mediated bFGF gene delivery can also protect RGCs from death in an optic nerve crush-injury model, with axotomized RGCs surviving for 1 week longer following AAV.bFGF delivery compared to sham-treated eyes. 83 AAVmediated CNTF delivery also enhances survival of axotomized RGCs. 84 However, in a model of optic nerve injury that combines ischaemia and axonal crush, it was shown that, although AAV-mediated CNTF delivery significantly protects RGCs and inner retinal neurons from death, it also causes a suppression of the ERG; ERG amplitudes are reduced by up to 50% in AAV.CNTFtreated eyes. 85 This demonstrates that in delivering neurotrophic factors that protect RGCs from death, preservation of retinal function must also be considered. AAV-mediated delivery of the gene encoding an antiapoptotic protein, Bcl-X L , allows survival of more than 40% of RGCs 8 weeks after optic nerve crush (compared with 15% in sham-treated eyes), 86 and combining this with AAV.GDNF delivery potentiates the treatment effect such that 67% of RGCs survive. 87 Damage to the optic nerve and loss of RGCs are also features of multiple sclerosis, which can be modelled in mice by inducing experimental allergic encephalomyelitis, using systemic sensitization with spinal emulsion. 88 In the eye, experimental allergic encephalomyelitis leads to the demyelination and loss of RGCs due to accumulation of free radical species of oxygen, such as superoxide and peroxynitrite, and the RGC loss can be attenuated by AAV-mediated delivery of antioxidant enzymes, such as extracellular and manganese superoxide dismutase, and catalase, for up to 6 months. 89, 90 Experimental retinal and choroidal neovascularization can be induced in mouse and rat eyes by causing transient relative hypoxia that produces a model of diabetic retinopathy or by creating laser lesions in the choroidal vasculature to cause choroidal neovascularization, a feature of AMD. Neovascularization can be inhibited by adenovirus-mediated or rAAV-mediated expression of vascular endothelial growth factor inhibitors, such as the soluble vascular endothelial growth factor receptor (sFlt-1), [91] [92] [93] angiostatin 94 or endostatin. 95 The size of laser-induced choroidal neovascularization lesions can also be reduced by a zinc-finger transcription factor that upregulates PEDF expression when delivered by AAV2. 96 Adenovirus-mediated overexpression of PEDF inhibits retinal and choroidal neovascularization, and furthermore, is reported to induce regression of established new vessels. The results of experimental studies have led to the development of a phase I clinical trial of adenovirus-mediated PEDF expression by intravitreal vector delivery in individuals with neovascular AMD. 97 Patients in this trial developed treatable inflammatory responses following vector administration, and only the group of patients receiving the highest dose of virus showed some improvements in outcome measures, such as neovascular lesion size. 97 To maximize the treatment potential of PEDF, a vector, such as AAV, that does not elicit immune responses would be better suited to delivering long-term, stable treatment effects.
Autoimmune posterior uveitis is an inflammatory disease affecting the eye, whereby immune responses to retinal antigens cause irreversible damage to photoreceptors. 98 The severity of experimental autoimmune uveoretinitis, induced by systemic inoculation with retinal peptides, can be reduced by adenovirus-mediated expression of the immuno-modulatory molecule, IL-10. rAAV2-mediated expression of IL-10 signicantly decreases disease severity of uveoretinitis without affecting splenocyte proliferative responses or serum antibody levels, illustrating the potential of gene therapy strategies to modulate immune responses in local microenvironments without unwanted systemic side effects. 99 AAV-mediated transgene expression in inner retinal cells may allow photoreception despite the total loss of photoreceptor cells
In circumstances where photoreceptor degeneration is too advanced to benefit from gene replacement or neuroprotection, new strategies to restore light sensitivity to the retina need to be explored. Alternatives include repairing the retina using cell transplantation 100 AAV-mediated gene therapy for retinal disorders PK Buch et al or electronic implants designed to stimulate responses from surviving inner retinal neurones. 101 A recent report describes the delivery of an algae-derived opsin analogue to neurons in the inner retina. In this study, an AAV2 vector was used to deliver the microbial Channelrhodopsin-2 (Chop2) gene to RGCs following intravitreal injection in rd1mice that lose all their photoreceptor cells. Chop2 expression results in sensitivity to light in the absence of phototransduction machinery as the Chop2 channel directly opens cation channels in the plasma membrane and causes action potentials when activated by light.
102 AAV2-mediated Chop2 expression in RGCs also ameliorates light-evoked potentials in the visual cortex, both in the rd1 mouse 102 and in 10-month-old RCS rats that have lost all their photoreceptors. 103 This suggests that the depolarization of transduced ganglion cells leads to perception of light in the brain. Although this is a promising approach, it does require further development, as Chop2-treated retinae only responded to light of the highest intensities tested, and creating lightsensitive RGCs bypasses the processing of the visual signal from bipolar cells. With better-regulated expression of the light-sensitive cation channel, this approach may yield a useful therapeutic paradigm for patients who present with end-stage photoreceptor degeneration and no light perception.
Translating AAV-mediated gene therapy from animal models to the clinic requires extensive assessments of safety and efficacy A recent phase I clinical trial of patients with end-stage retinitis pigmentosa demonstrated that a cell-based device secreting CNTF is well tolerated for a number of months, but assessments of the impact on visual function were difficult to interpret due to the small number of patients treated. This study demonstrates the difficulty in interpreting results obtained in animal studies and extrapolating them to likely outcomes in patients. As experiments in rodents show, sustained exposure to CNTF is known to cause dose-dependant deleterious effects in terms of retinal function, but the small-scale phase I study showed that short-term CNTF delivery (implants were removed after 6 months) at low doses could be well tolerated. It remains to be seen whether similar doses will have any efficacy in maintaining useful vision, in particular cone-mediated central vision, in patients with the wide range of retinal disorders being targeted in the phase II/III trial initiated recently. As the implications of data from long-term experiments in rodents are a cause for concern, the results of this expanded trial are eagerly anticipated. Any demonstration of efficacy in the absence of significant side effects would represent a milestone in the treatment of retinal degeneration and would argue for the sustained AAVmediated delivery of neurotrophic factors in future trials.
The extensive research effort in developing AAVbased gene replacement therapy for RPE65 deficiency has supported the translation of preclinical studies into phase I and II clinical trials. Three such trials have now commenced, the first at the UCL Institute of Ophthalmology and Moorfields Eye Hospital, and two more in the United States-one is a collaboration between Scheie's Center for Hereditary Retinal Degenerations, University of Pennsylvania and the University of Florida College of Medicine in Gainesville, and the other is at University of Pennsylvania (USA) and Children's Hospital of Philadelphia. As these trials represent the first approach to AAV-mediated transgene delivery in the eye, each of the trials have a strong emphasis on evaluating safety and toxicity. They have all commenced with adult subjects who have advanced disease. Although it is hoped that some improvement in visual function will be detected, data from preclinical studies suggest that it is likely that therapy will be most effective in younger patients with less advanced photoreceptor loss. Should the subretinal delivery of AAV vector be shown to be well tolerated, younger subjects will be treated in each trial. All the three concurrent trials use a similar vector but the protocols differ in terms of vector design and inclusion criteria. All three trials use AAV vectors to deliver RPE65 because of its strong track record in terms of mediating safe and effective therapeutic gene expression in the RPE. The use of promoter sequences, however, differs between the trials. The use of a strong constitutive promoter is likely to result in maximal efficiency of RPE65 expression, whereas using the endogenous RPE65 promoter in an attempt to achieve targeted physiological expression might produce a different safety profile or therapeutic effect. It is hoped that the different protocols will inform optimal vector design for future interventions by yielding complementary data on vector titre, inclusion criteria and promoter sequences.
The potential of AAV-mediated gene therapy for the treatment of IRD and for a range of acquired ocular disorders has been extensively validated in preclinical studies. The three current clinical studies of AAVmediated gene therapy for RPE65 deficiency are a landmark for the development of ocular gene therapy. The trials are key for establishing the safety of subretinal AAV delivery and for paving the way for further human studies.
